Seham Ibrahim - Integrated Diagnostics Sales Director
| IDHC Stock | 0.44 0.01 2.22% |
Director
Seham Ibrahim is Sales Director of Integrated Diagnostics Holdings
| Age | 55 |
| Address | IFC 5, Saint Helier, Jersey, JE1 1ST |
| Phone | 44 15 3484 7000 |
| Web | https://www.idhcorp.com |
Integrated Diagnostics Management Efficiency
The company has return on total asset (ROA) of 0.0969 % which means that it generated a profit of $0.0969 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2303 %, meaning that it generated $0.2303 on every $100 dollars invested by stockholders. Integrated Diagnostics' management efficiency ratios could be used to measure how well Integrated Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Integrated Diagnostics' Other Current Assets are comparatively stable compared to the past year. Other Assets is likely to gain to about 9.6 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 B in 2024.Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Andrew ACA | Fevertree Drinks Plc | 45 | |
| Oliver Winters | Fevertree Drinks Plc | N/A | |
| Rachel Tongue | Games Workshop Group | 53 | |
| Elizabeth Harrison | Games Workshop Group | N/A | |
| Timothy Stacey | DFS Furniture PLC | 53 | |
| Saskia Stoop | Fevertree Drinks Plc | 40 | |
| Ann Hyams | Fevertree Drinks Plc | N/A | |
| Andrew Branchflower | Fevertree Drinks Plc | 45 | |
| William Castell | Gamma Communications PLC | 46 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0969 |
Integrated Diagnostics Leadership Team
Elected by the shareholders, the Integrated Diagnostics' board of directors comprises two types of representatives: Integrated Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integrated. The board's role is to monitor Integrated Diagnostics' management team and ensure that shareholders' interests are well served. Integrated Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integrated Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sherif Zeiny, Group Director | ||
| Amid Abdelnour, Managing Biolab | ||
| Eissa Khorshid, Chief Officer | ||
| Osama Zaghloul, Managing Ultralab | ||
| Tarek Yehia, Director Relations | ||
| Omar Bedewy, Group Strategies | ||
| Moushira Saifi, Head Department | ||
| Nancy Fahmy, Investor Director | ||
| Seham Ibrahim, Sales Director | ||
| Hend Sherbini, Group Director | ||
| Mohamed Saleh, General Counsel | ||
| Mohamed Nouh, Head Administrator |
Integrated Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integrated Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0969 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 261.19 M | ||||
| Shares Outstanding | 581.33 M | ||||
| Shares Owned By Insiders | 33.97 % | ||||
| Shares Owned By Institutions | 42.29 % | ||||
| Price To Book | 4.77 X | ||||
| Price To Sales | 0.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Integrated Stock Analysis
When running Integrated Diagnostics' price analysis, check to measure Integrated Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Diagnostics is operating at the current time. Most of Integrated Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integrated Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Diagnostics' price. Additionally, you may evaluate how the addition of Integrated Diagnostics to your portfolios can decrease your overall portfolio volatility.